Tokyo. A group of Japanese scientists announced this Friday transplanted induced pluripotent stem cells (iPS) in the brain of the affected patient Parkinson, the first attempt of this kind in the world.
A team from the University of Kyoto injected 2.4 million iPS cells – able to generate any kind of cells – in the left part of the brain during a three-hour operation carried out in October.
The man, about 50 years old, tolerated the treatment well and would remain under observation for two years, said the Kyoto University in a statement.
If there is a problem in the next six months, the scientists will eliminate 2.4 million additional cells, this time in the right part of the brain.
These iPS cells from healthy donors should develop into the generated neurons dopamine, a neurotransmitter that intervenes in the control of motor skills.
The University of Kyoto announced in July that it will conduct a clinical trial of seven people aged 50-69.
Parkinson's disease is characterized by neuronal degeneration, with symptoms that gradually increase, such as tremor, muscle stiffness and loss of the body's ability to move.
This applies to more than ten million people in the world, according to the Foundation against Diseases Parkinson AmericanThe currently available therapies "improve symptoms without slowing the progression of the disease," explains the foundation.
New investigations aim to reverse the evil.
Before the human clinical trial, an experiment was carried out on monkeys with stem cells of human origin that improved the ability to move the primate affected by Parkinson's disease, according to a study published at the end of August 2017. In the scientific journal Nature,
For two years, the survival rate of the transplanted cells was closely monitored by injection into the primate brain and no cancer was detected.
Induced pluripotent stem cells (iPS) are adult cells reduced to an almost embryonic state to generate four genes (usually inactive in adults). This genetic manipulation restores the ability to produce any cell depending on the place of the body in which they are transplanted.
The use of iPS cells does not cause significant ethical problems, unlike stem cells derived from human embryos.